MedTrace Logo

Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism

NCT00220298 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2014-12-30

No results posted yet for this study

Summary

This study will evaluate the preparation of testosterone undecanoate under conditions which resemble real-life situations.

Conditions

  • Hypogonadism

Interventions

DRUG

Testosterone undecanoate (TU) - NebidoTM

Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220298 on ClinicalTrials.gov